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Abstract 
Background: Protein arginine methyltransferase 5 (PRMT5), a type II PRMT, is highly expressed in some tumors, but 
its role in hepatocellular carcinoma (HCC) is still unknown.
Methods: PRMT5 level in HCC specimens was determined by immunohistochemical staining and the association 
with clinicopathologic features was evaluated. PRMT5 was inhibited by AMI-1 (a small molecule inhibitor of PRMTs) 
or small interference RNA (siRNA). The proliferation of HCC cells was tested by Cell Counting Kit-8, cell migration was 
evaluated by Transwell assay and cell cycle and apoptosis were analyzed by flow cytometry. The effect of AMI-1 on 
HCC in vivo was examined by mouse xenograft model.
Results: PRMT5 expression was markedly upregulated in HCC tissues, and correlated inversely with overall patient 
survival. Knockdown of PRMT5 significantly reduced the proliferation of HCC cells, but did not affect the growth of 
normal liver cells. Furthermore, β-catenin was identified as a target of PRMT5. Silencing PRMT5 significantly down-reg-
ulated the expression of β-catenin and the downstream effector Cyclin D1 in HCC cells. AMI-1 strongly inhibited HCC 
growth in vivo, increased the ratio of Bax/Bcl-2, and led to apoptosis and loss of migratory activity in several HCC cells. 
Meanwhile, AMI-1 decreased the expression levels of symmetric dimethylation of H4 (H4R3me2s), a histone mark of 
PRMT5.
Conclusions: PRMT5 plays an important role in HCC. PRMT5 may be a promising target for HCC therapy.
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Background
Hepatocellular carcinoma (HCC) is the fifth leading can-
cer and the third most common cause for cancer death 
worldwide [1–3]. The overall survival of patients with 
HCC is less than 10 %. Surgical resection and liver trans-
plantation is the main therapeutic strategy for HCC if 
patients are diagnosed at an early stage [4]. However, a 
majority of patients with HCC present with advanced 
disease and treatment options are limited [5]. Sorafenib 
has been recognized as the most effective targeted ther-
apeutic agent for advanced HCC. However, compared 
with placebo groups, sorafenib only increased survival 
from 7.9 to 10.7  months [6]. Therefore, it is urgent to 
develop more effective therapeutic strategies and agents 
to treat HCC.
Protein arginine methyltransferase 5 (PRMT5), a 
type II arginine methyltransferase, is localized in both 
cytoplasm and the nucleus of mammalian cells [7, 8]. 
PRMT5-driven methylation of arginine residues leads 
to symmetric dimethylation of histone H3 (H3R8me2s) 
and H4 (H4R3me2s), which in turn alter chromatin 
structure to regulate gene expression [9, 10]. PRMT5 
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has been found to be overexpressed in multiple tumor 
types, including leukemia, lymphoma, lung cancer, colo-
rectal cancer and breast cancer [11–15]. However, the 
role of PRMT5 in hepatocarcinogenesis has not been 
established.
In this study we aimed to investigate the role of PRMT5 
in hepatocarcinogenesis by using in  vitro and in  vivo 
models. We showed that PRMT5 protein is overex-
pressed in HCC tumor tissues, and its elevated level is 
associated with worse prognosis in patients with HCC. 
In addition, we found that specific deletion of PRMT5 
by small interference RNA (siRNA) or the inhibition 
of its activity by arginine methyltransferase inhibitor 1 
(AMI-1) significantly decreases HCC development. Fur-
thermore, we demonstrate that the deletion of PRMT5 
significantly down-regulates the expression of β-catenin 
and its downstream effector Cyclin D1 in HCC cells.
Methods
Human tissue samples and cell lines
Fifty-four pairs of HCC tissues and corresponding nor-
mal adjacent tissues (NATs) were purchased from the 
National Engineering Center for Biochips (Shang-
hai, China). All human materials were obtained with 
informed consent, and this study was approved by Ethics 
Committee of Lanzhou University. Four human HCC cell 
lines (HepG2, Bel-7404, Bel-7402 and SMMC-7721), one 
rat hepatoma cell line CBRH-7919 and one normal liver 
cell line HL-7702 were purchased from American Type 
Culture Collection (Manassas, VA, USA), and cultured 
under conditions recommended.
Immunohistochemical staining
Tissue arrays were constructed using 54 pairs of HCC 
tissues and corresponding NATs. Immunohistochemi-
cal staining was performed on 4 μm sections of paraffin-
embedded human HCC tissues and matched NATs to 
determine the expression level of PRMT5 protein. Briefly, 
the slides were incubated with PRMT5 antibody at 4  °C 
overnight. After extensive washing, the sections were 
incubated with secondary antibody, followed by staining 
with DAB (ZSGB-BIO, Beijing, China). The slides were 
then washed and counterstained with hematoxylin. A 
semiquantitative scoring method according to the overall 
staining of the cells was applied for immunohistochemis-
try (IHC) [16, 17].
RNA interference
Three different siRNA each were synthesized against 
human PRMT5 by Ribobio (Guangzhou, China), and 
the most effective one (target sequence: CCGCTATT 
GCACCTTGGAA) was selected for the subsequent 
experiments with test siRNA. Cells were transfected with 
PRMT5 siRNA (si-PRMT5, final concentration of 50 nM) 
or scramble siRNA (Negative control siRNA, si-NC) 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, 
USA) according to manufacturer’s protocol.
Cell proliferation assay and colony formation assay
Cells were seeded in flat-bottom 96-well plates (2.5 × 103 
cells per well) in triplicate. After 24 h, cells were treated 
with si-NC, si-PRMT5 or AMI-1. Then cell proliferation 
was assessed using the Cell Counting Kit-8 (Dojindo, 
Tokyo, Japan) according to the manufacturer’s protocols. 
The efficacy of the treatment was expressed as best tumor 
growth inhibition [18, 19]. The T/C value was calculated 
as follows: %T/C  =  (median tumor weight of treated 
tumors/median tumor weight of control tumors) × 100. 
For the colony formation assay, HepG2 and HL-7702 
cells were placed in 60  mm dishes at 200 cells per dish 
and maintained in the absence or presence of si-PRMT5 
for 16 days. Cells were fixed with fixative (7 parts metha-
nol: 1 part glacial acetic acid) for 15 min and then stained 
with crystal violet (0.2 g/L) for 30 min.
Cell cycle analysis and apoptosis assay
Cell cycle and apoptosis were analyzed by flow cytometry 
as described previously [20, 21]. Briefly, cells were seeded 
at 1 × 105 cells/well in 6-well plates and transfected with 
si-NC or si-PRMT5. After 72  h, cells were harvested 
using 0.25  % trypsin without EDTA and fixed in 75  % 
ethyl alcohol at −20  °C overnight. The next day, cells 
were exposed to 40 mg/ml propidium iodide and 100 mg/
mL ribonuclease A in PBS for 30  min at room temper-
ature in the dark. Cell DNA content was then analyzed 
using FACS. For apoptosis assay, the treated cells were 
harvested using 0.25 % trypsin, washed twice and resus-
pended in Binding Buffer at concentration of 1  ×  106 
cells/mL. 500 µL of cells were incubated with 5  µL of 
Annexin V-FITC and 5 µL of Propidium Iodide for 5 min 
at room temperature in the dark. The samples were then 
evaluated by FACS (Navios, Beckman Coulter, CA, USA).
Western blot analysis
Cell lysates were separated in 12  % SDS–polyacryla-
mide gel electrophoresis, and then transferred to PVDF 
membrane (Bio-Rad). After being blocked with 5  % 
non-fat milk for 1  h, the membranes were incubated 
with the following primary antibodies at 4 °C overnight: 
PRMT5 (1:400; Santa Cruz Biotech, Santa Cruz, CA, 
USA), PRMT7 (1:500; Santa Cruz Biotech), Cyclin D1 
(1:500; Santa Cruz Biotech), CTNNB1 (β-catenin, 1:1000; 
ABclonal, MA, USA), H4R3me2s (1:2000; Abcam, 
MA,  USA), H3R8me2s (1:250; Novus, CO, USA), Bax 
(1:1000; Cell Signaling, MA, USA), Bcl-2 (1:1000; Cell 
Signaling), PRMT7 (1:1000; Cell Signaling) or β-actin 
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(1:2000; Cell Signaling), and then incubated with sec-
ondary antibodies conjugated to horseradish peroxidase 
(ZSGB-BIO, Beijing, China). Immuno-reactivity was 
visualized using ECL Western blotting detection reagents 
and then analyzed by densitometry.
Migration assay
Cell migration assay was performed in 24-well tran-
swell chambers, 8 µm pore size Transwell plate (Corning 
Inc.; NY, USA) [22, 23]. In brief, the cells resuspended 
in 100 µL serum-free medium (4  ×  104 cells per well) 
were placed in upper chamber of insert in triplicate 
and medium with 600 µL 10 % FBS was used as chemo-
attractant in lower chamber. AMI-1 or vehicle control 
was added to inner chamber. After 24 h, the cells remain-
ing on the top surface of the membrane were removed 
with a cotton swab. The cells on the bottom surface of the 
membrane were fixed in methanol and stained with 0.2 % 
crystal violet.
Human HCC xenograft model
Female athymic BALB/c nude mice were purchased from 
Shanghai SLAC Laboratory Animal Co. Ltd (Shanghai, 
China) and maintained under specific pathogen-free 
room with a 12-h on/off light cycle, and fed autoclaved 
chow and water. Mice were manipulated and housed 
according to protocols approved by the Institutional Ani-
mal Care and Treatment Committee of Lanzhou Univer-
sity. 5 × 106 HepG2 cells were inoculated subcutaneously 
(s.c) in the right flank of 5–6-week old healthy BALB/c 
nude mice. When tumors reached an average volume of 
about 70  mm3, the mice bearing too large or too small 
tumors were eliminated and the left were randomly 
divided into two treatment groups (8 animals per group): 
AMI-1 (0.5  mg in 100 µL of 0.9  % NaCl) or 100 µL of 
0.9  % NaCl were administered intratumorly (i.t) twice a 
week. Control animals and animals treated with AMI-1 
were sacrificed after 36 days and tumor were excised and 
weighted. Tumor volumes were calculated according to 
the following formula: (length × width2) × 0.52.
Statistical analysis
Unless otherwise stated, data were presented as the 
mean ± SD and subjected to student’s t test. Differences 
were considered statistically significant as *P  <  0.05, 
**P < 0.01 or ***P < 0.001.
Results
PRMT5 is overexpressed in primary HCC tumors
To evaluate the clinical significance of PRMT5 in HCC 
development, we analyzed PRMT5 level and its distri-
bution in HCC tissues by immunohistochemical (IHC) 
staining. The array included the cancer tissue samples 
and corresponding normal adjacent tissues (NATs) 
from 54 HCC patients, which consisted of 48 males 
and 6 females, with a medium age of 53  years (range 
38–72  years). Among the patients 31 (57.4  %) died of 
tumor related to causes, and 23 (42.6 %) were still alive 
as of the last follow-up (Table  1). PRMT5 levels in the 
tissues array specimens were assessed based on the 
staining density scores. We found that in cancer tissues, 
31 cases (57.4 %) exhibited strong immunopositivity, 18 
cases (33.3  %) exhibited moderate immunopositivity, 
and 5 cases (9.3 %) exhibited no or weak immunopositiv-
ity. In contrast, the majority of normal tissues (51.9  %) 
exhibited no or weak PRMT5 expression (Table  2). 
Statistical analysis revealed that PRMT5 level signifi-
cantly increased in cancer tissues compared with the 
corresponding NATs (Fig. 1A, B). In addition, cytoplas-
mic PRMT5 level, but not nuclear PRMT5 level, had a 
trend to be negatively correlated with the survival rate 
of the patients with HCC (Fig.  1C). As negative con-
trol, PRMT5 antibody could not detect positive stain-
ing (Additional file  1: Figure  1). Notably, no significant 
association was found between PRMT5 expression in 
Table 1 Clinical and  pathological characteristics of   
patients with HCC (n = 54)




 Male 48 88.9 3.8542 0.369
 Female 6 11.1 3.3333
Age (years)
 ≤50 17 31.5 3.2059 0.034
 >50 37 68.5 4.0135
Tumor size (cm)
 ≤5 27 50 3.8611 0.573
 >5 27 50 3.6574
TNM stage
 I 6 11.1 4.0833 0.259
 II 37 68.5 3.6757
 III 11 20.4 8.8636
Table 2 Summary of PRMT5 scoring distribution
P value calculated by χ2 test for normal liver tissue versus HCC tissue




<2 (weak immunopositivity) 28 (51.9 %) 5 (9.3 %)
2–4 (moderate immunopositivity) 22 (40.7 %) 18 (33.3 %)
≥4 (strong immunopositivity) 4 (7.4 %) 31 (57.4 %)
P values <0.0001
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HCC and tumor size or TNM stage (P > 0.05, Table 1). 
Univariate Cox regression analyses showed that PRMT5 
expression in the cytoplasm was significantly correlated 
with overall survival (Table  3). Furthermore, multivari-
ate Cox regression analysis confirmed that cytoplasmic 
PRMT5 expression could serve as independent predic-
tor of the overall survival of patients with HCC (Table 3). 
In addition, we performed Western blot analysis to 
determine of PRMT5 protein level in several HCC cell 
lines. As shown in Additional file  1: Figure  2, PRMT5 
was expressed in normal liver HL-7702 cells and highly 
expressed in Bel-7704, HepG2 and CBRH-7919 HCC cell 
lines. Taken together, these results indicate that PRMT5 
overexpressed is tightly linked to HCC proliferation and 
development.   
Knockdown of PRMT5 suppresses HCC cell proliferation 
in vitro
To determine the role of PRMT5 in HCC cell prolif-
eration, we employed siRNA against human PRMT5 to 
knockdown PRMT5 in two human HCC cells (HepG2 
and Bel-7404) and one normal liver cell (HL-7702), and 
then cell proliferation was measured by CCK-8 assay. 
As shown in Fig.  2a–c, silencing PRMT5 significantly 
decreased proliferation and colony formation of HCC 
cells, but not normal hepatocyte HL-7702. In addition, 
because PRMT5 and PRMT7 have been shown to pos-
sess type II methyltransferase activity [24, 25], we tested 
the specificity of si-PRMT5 in HCC cell lines. The results 
showed that si-PRMT5 did not affect the protein levels of 
PRMT7 (data not shown).
Fig. 1 Upregulation of PRMT5 in HCC tissues and its association with poor survival. A Immunohistochemical staining of PRMT5 in HCC tissues and 
corresponding NATs. Positive cells were stained brown. Magnification, (a, c) ×50; (b, d) ×100; scale bar 50 μm. B PRMT5 scores based on the nuclear 
or cytoplasmic levels of expression in 54 HCC patients, compared with matched normal tissues. C Association between PRMT5 expression and the 
survival of HCC patients
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Knockdown of PRMT5 induces HCC cell cycle arrest
To explore the mechanism by which PRMT5 knockdown 
inhibits HCC cell proliferation, we performed cell cycle 
analysis. As shown in Fig.  2d, PRMT5 knockdown led 
to an increase of cell population at the G1 phase, with a 
corresponding decrease in S and G2/M phase, compared 
with si-NC, indicating that PRMT5 may be required for 
the G1-to-S phase transition.
To understand underlying mechanism of cell cycle 
arrest, the levels of several cell proliferation/cycle-
related proteins in si-NC and PRMT5-knockdown 
HCC cells were analyzed by Western blot analysis. As 
shown in Fig.  2e, knockdown of PRMT5 significantly 
decreased the expression of β-catenin and Cyclin D1 
in HCC cells. These results indicate that PRMT5 pro-
motes cell cycle progression by regulating the expres-
sion of cell cycle-related proteins such as β-catenin and 
Cyclin D1.
Because PRMT5-driven methylation of arginine resi-
dues leads to H4R3me2s and H3R8me2s, we then meas-
ured H4R3me2s and H3R8me2s in HCC cells treated 
with si-PRMT5. We found that the levels of H4R3me2s 
and H3R8me2s were significantly decreased compared 
with si-NC (Fig. 2f ).
AMI‑1 inhibits HCC cell proliferation in vitro and in vivo
AMI-1 has been applied to inhibit type I PRMT (PRMT1, 
3, 4, and 6) activity in vitro [26]. Interestingly, we found 
that AMI-1 also inhibited 84.2  % of type II PRMT5 
activity at the tested concentration (nearly 50 µM) [27]. 
Therefore, we examined the in vitro and in vivo efficacy 
of AMI-1 on HCC using human HCC cell lines and xeno-
graft mouse models. The concentrations of AMI-1 used 
for in  vitro and in  vivo experiments and for enzymatic 
assay are different, based on our preliminary experi-
ments and previous literatures [27–30]. As shown in 
Fig.  3a, AMI-1 elicited a significant inhibition on HCC 
cell growth. In animal tumor models, the tumors were 
injected with AMI-1 intratumorly (i.t.), because the drug 
via systemic delivery is easily denatured or degraded. 
We found that treatment with AMI-1 reduced tumor 
weight by 65.1 % compared with control-treated animals 
(Fig. 3b).
AMI‑1 inhibits PRMT5 activity and induces apoptosis 
in HCC cells
To further explore the mechanism of PRMT5 action in 
HCC, Western blot analysis was performed to determine 
protein levels of Bax and Bcl-2 in HCC cells. The results 
Table 3 Univariate and multivariate analyses of the survival of HCC patients
The Cox proportional hazards regression model was used for univariate and multivariate analyses to study the effects of the clinicopathological variables and PRMT5 
expression on survival
HR hazard ratio, CI confidence interval
Covariate n Univariate analysis Multivariate analysis
HR 95 % CI P value HR 95 % CI P value
Gender 0.710 0.758
 Male 48 1.000 1.000
 Female 6 1.254 0.381–4.126 1.232 0.326–4.654
Age (years) 0.812 0.371
 ≤50 17 1.000 1.000
 >50 37 1.099 0.506–2.387 0.671 0.280–1.609
Tumor size (cm) 0.037 0.062
 ≤5 27 1.000 1.000
 >5 27 2.170 1.046–4.504 2.148 0.964 4.785
TNM stage 0.105 0.329
 I 6 1.000 1.000
 II 37 1.087 0.323–3.659
 III 11 2.395 0.633–9.058 1.459 0.683–3.116
Cytoplasmic PRMT5 0.033 0.029
 Low 36 1.000 1.000
 High 18 2.175 1.067–4.435 2.411 1.094–5.313
Nuclear PRMT5 0.963 0.691
 Low 40 1.000 1.000
 High 14 1.020 0.439–2.369 1.228 0.446–3.380
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showed that AMI-1 increased Bax/Bcl-2 ratio associated 
with apoptosis relative to control cells (Fig. 3c). As shown 
in Fig.  3c, d, the expression of H4R3me2s protein was 
significantly decreased in AMI-1 treated cells compared 
with control cells. These results indicate that AMI-1 
inhibits HCC growth, at least partially through inhibiting 
PRMT5 activity in HCC cells.
PRMT5 inhibition promotes the apoptosis while inhibits 
the migration of HCC cells
Inhibition of PRMT5 overexpression can induce apopto-
sis in different types of cancer [24, 31, 32]. To investigate 
the effect of AMI-1 on HCC cell viability, Bel-7402 and 
HepG2 cells were treated with either AMI-1 or vehicle 
only, and apoptosis was determined by Annexin V-FITC/
propidium iodide staining and flow cytometry. As shown 
in Fig.  4a, PRMT5 inhibition by AMI-1 resulted in the 
induction of apoptosis/death in both cells compared with 
control cells. In addition, transwell assay showed that 
treatment of HCC cells with AMI-1 resulted in marked 
reduction in migration activity compared with control 
group (Fig.  4b). Furthermore, we employed siRNA to 
knockdown PRMT5 in HCC cells and found that PRMT5 
siRNA increased the apoptosis while decreased the 
migration of HCC cells (Additional file 1: Figure 3).
Discussion
PRMT5 emerges as an important regulator of multiple 
cellular processes and is expressed aberrantly in different 
types of cancer [11–15]. However, the role of PRMT5 in 
the pathogenesis of HCC and the relationship between 
PRMT5 expression and clinicopathological factors of 
HCC are largely unknown. In this study, we found that 
PRMT5 expression was markedly up-regulated in HCC 
tissues compared with NATs, and that higher expression 
of PRMT5 in the cytoplasm was significantly correlated 
with poor prognosis of HCC patients. Furthermore, we 
demonstrated that PRMT5 knockdown by siRNA could 
significantly inhibit the proliferation and colony forma-
tion of HCC cells, and repress cell cycle progression by 
inducing G0/G1 cell cycle arrest. Collectively, these data 
indicate that PRMT5 may function as an oncogene and 
is a key mediator in carcinogenesis and progression of 
HCC.
Wnt/β-catenin signaling is frequently activated 
in HCC, but the causes of its activation are not well 
Fig. 2 Silencing PRMT5 decreases human HCC cell growth in vitro. a HepG2 and Bel-7404 cells were transfected with PRMT5 siRNA (si-PRMT5) or 
scramble negative control siRNA (si-NC) and cell proliferation was analyzed. b Normal liver HL-7702 cells were transfected with PRMT5 siRNA (si-
PRMT5) or scramble negative control siRNA (si-NC) and cell proliferation was analyzed. c The effect of si-PRMT5 on colony formation of HepG2 and 
HL-7702 cells. Representative results of colony formation of vehicle (left), si-NC (middle), and si-PRMT5 (right) HepG2 and HL-7702 cells. 5-fluorouracil 
(5-Fu) is used as a positive control. d Knockdown of PRMT5 led to G1 arrest. HepG2 cells were transfected with si-NC or si-PRMT5 and then subjected 
to cell cycle analysis. e and f Western blot analysis of whole-cell lysates derived from HepG2 cells transfected with si-NC or si-PRMT5 using antibod-
ies against PRMT5, β-catenin, Cyclin D1, H4R3me2s or H3R8me2s
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understood [33]. Cytoplasmic and nuclear accumulations 
of β-catenin occur in 40–70 % of HCCs [34]. Upon Wnt 
activation, accumulated β-catenin enters the nucleus and 
binds to T-cell factor/lymphoid enhancer factor (TCF/
LEF) to activate the transcription of Wnt target genes 
[35, 36]. A key event in both Wnt signaling and cancer 
cell proliferation is the regulation of β-catenin stability 
and activity. Our results showed that silencing PRMT5 
significantly attenuates the expression levels of β-catenin 
and Cyclin D1. As Cyclin D1 is a downstream target of 
Wnt/β-catenin pathway and plays a key role as a regu-
lator of cell proliferation [37], these data suggest that 
PRMT5 might mediate HCC tumor proliferation and 
development by regulating Cyclin D1 through Wnt/β-
catenin pathway. This finding also suggests that PRMT5 
mediated methylation is bi-functional, either repressing 
or promoting transcription, depending on what genes are 
expressed [38]. Additional studies will be required to dis-
tinguish the multiple potential mechanisms for PRMT5 
function in different events of gene expression regulation.
There are several strategies to inhibit PRMT5 overex-
pression in cancer. In this study, we demonstrated that 
knockdown of PRMT5 by siRNA effectively inhibited 
HCC cell proliferation and colony formation in vitro, but 
treatment with siRNA is still in the experimental stage 
[39, 40]. Moreover, as no specific potent inhibitors are 
yet available for members of the PRMT enzyme family 
[25], our efforts focus on the discovery and development 
of small molecule inhibitors of PRMT5. AMI-1, a sym-
metrical sulfonated urea, was discovered by Cheng et al. 
[26]. However, AMI-1 has been applied to inhibit type I 
PRMT activity only in vitro experiments.
PRMTs are classified as either type I or type II. Both 
types can catalyze the formation of omega-N monometh-
ylarginine (MMA) as an intermediate, and type I PRMTs 
(PRMT1, PRMT3, PRMT4, and PRMT6) lead to the 
production of asymmetrical dimethylarginine (aDMA), 
whereas type II PRMTs (PRMT5 and PRMT7) catalyze 
the formation of symmetrical dimethylarginine (sDMA) 
[41]. In this study, we first demonstrated that AMI-1 
inhibited HCC growth in vitro and in vivo. Furthermore, 
we detected the expression of apoptosis related proteins 
such as Bax and Bcl-2 and found that AMI-1 up-regu-
lated Bax/Bcl-2 ratio in HCC cells. AMI-1 also induced 
Fig. 3 AMI-1 inhibits HCC cell growth in vitro and in vivo. a The effect of AMI-1 on the proliferation of human HCC cell lines. b The effect of AMI-1 
on tumor formation in a nude mouse xenograft model. c The expression of Bax, Bcl-2 and H4R3me2s in HepG2 cells treated with AMI-1 for 72 h. d 
Densitometric analysis of band intensities. β-actin was loading control. Control refers to vehicle-treated group
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apoptosis and decreased migratory activity in several 
HCC cell lines. In addition, AMI-1 decreased the expres-
sion levels of H4R3me2s, a histone marker of PRMT5. 
These data suggest that AMI-1 exhibits anti-tumor 
effects against HCC, at least in part through inhibitting 
PRMT5.
Fig. 4 AMI-1 promotes the apoptosis and decreases migratory activity of HCC cells. a HCC cells were treated with vehicle or AMI-I and then stained 
by Annexin V-fluorescein isothicyanate (FITC) and propidium iodide (PI), followed by flow cytometry analysis. b AMI-1 decreased migratory activity 
of HCC cells measured by Transwell assay. Representative photos of stained cells are shown. Original magnification ×200. Control refers to vehicle-
treated group
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Conclusion
These results strongly indicate that PRMT5 is frequently 
up-regulated and inversely correlated with poor progno-
sis in HCC patients. PRMT5 might function as an onco-
gene partly by mediating the repression of β-catenin and 
its downstream target Cyclin D1 in HCC. Therefore, 
PRMT5 might be a potential biomarker and a promising 
therapeutic target for HCC.
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